Stereotactic body radiation therapy for prostate cancer

Hiromichi Ishiyama; Bin S. Teh; Simon S. Lo; Thomas Mathews; Angel Blanco; Robert Amato; Rodney J. Ellis; Nina A. Mayr; Arnold C. Paulino; Bo Xu; Brian E. Butler

doi:10.2217/fon.11.86

Stereotactic body radiation therapy for prostate cancer

Hiromichi Ishiyama, Bin S. Teh, Simon S. Lo, Thomas Mathews, Angel Blanco, Robert Amato, Rodney J. Ellis, Nina A. Mayr, Arnold C. Paulino, Bo Xu, Brian E. Butler

Research output: Contribution to journal › Review article › peer-review

7 Scopus citations

Abstract

Stereotactic body radiation therapy (SBRT) is a promising treatment option for prostate cancer. Hypofractionation regimens, such as SBRT, may be more advantageous compared with conventional regimens because low α:β ratio of prostate cancer has high sensitivity to dose per fraction. In addition, a smaller and tighter margin with SBRT is expected to provide a low toxicity rate without reducing tumor control. The purpose of this article is to examine radiobiological, technical and clinical aspects of SBRT for prostate cancer.

Original language	English (US)
Pages (from-to)	1077-1086
Number of pages	10
Journal	Future Oncology
Volume	7
Issue number	9
DOIs	https://doi.org/10.2217/fon.11.86
State	Published - Sep 2011

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/fon.11.86

Cite this

@article{67971f222b0f43c29bf82e41ac1a2b23,

title = "Stereotactic body radiation therapy for prostate cancer",

abstract = "Stereotactic body radiation therapy (SBRT) is a promising treatment option for prostate cancer. Hypofractionation regimens, such as SBRT, may be more advantageous compared with conventional regimens because low α:β ratio of prostate cancer has high sensitivity to dose per fraction. In addition, a smaller and tighter margin with SBRT is expected to provide a low toxicity rate without reducing tumor control. The purpose of this article is to examine radiobiological, technical and clinical aspects of SBRT for prostate cancer.",

author = "Hiromichi Ishiyama and Teh, \{Bin S.\} and Lo, \{Simon S.\} and Thomas Mathews and Angel Blanco and Robert Amato and Ellis, \{Rodney J.\} and Mayr, \{Nina A.\} and Paulino, \{Arnold C.\} and Bo Xu and Butler, \{Brian E.\}",

year = "2011",

month = sep,

doi = "10.2217/fon.11.86",

language = "English (US)",

volume = "7",

pages = "1077--1086",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Taylor and Francis Ltd.",

number = "9",

}

TY - JOUR

T1 - Stereotactic body radiation therapy for prostate cancer

AU - Ishiyama, Hiromichi

AU - Teh, Bin S.

AU - Lo, Simon S.

AU - Mathews, Thomas

AU - Blanco, Angel

AU - Amato, Robert

AU - Ellis, Rodney J.

AU - Mayr, Nina A.

AU - Paulino, Arnold C.

AU - Xu, Bo

AU - Butler, Brian E.

PY - 2011/9

Y1 - 2011/9

N2 - Stereotactic body radiation therapy (SBRT) is a promising treatment option for prostate cancer. Hypofractionation regimens, such as SBRT, may be more advantageous compared with conventional regimens because low α:β ratio of prostate cancer has high sensitivity to dose per fraction. In addition, a smaller and tighter margin with SBRT is expected to provide a low toxicity rate without reducing tumor control. The purpose of this article is to examine radiobiological, technical and clinical aspects of SBRT for prostate cancer.

AB - Stereotactic body radiation therapy (SBRT) is a promising treatment option for prostate cancer. Hypofractionation regimens, such as SBRT, may be more advantageous compared with conventional regimens because low α:β ratio of prostate cancer has high sensitivity to dose per fraction. In addition, a smaller and tighter margin with SBRT is expected to provide a low toxicity rate without reducing tumor control. The purpose of this article is to examine radiobiological, technical and clinical aspects of SBRT for prostate cancer.

UR - https://www.scopus.com/pages/publications/80052975026

UR - https://www.scopus.com/inward/citedby.url?scp=80052975026&partnerID=8YFLogxK

U2 - 10.2217/fon.11.86

DO - 10.2217/fon.11.86

M3 - Review article

C2 - 21919695

AN - SCOPUS:80052975026

SN - 1479-6694

VL - 7

SP - 1077

EP - 1086

JO - Future Oncology

JF - Future Oncology

IS - 9

ER -

Stereotactic body radiation therapy for prostate cancer

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this